U.S. Markets open in 4 hrs 23 mins
  • S&P Futures

    3,249.00
    -53.25 (-1.61%)
     
  • Dow Futures

    26,125.00
    -432.00 (-1.63%)
     
  • Nasdaq Futures

    11,106.75
    -236.00 (-2.08%)
     
  • Russell 2000 Futures

    1,537.60
    -20.80 (-1.33%)
     
  • Crude Oil

    36.25
    +0.08 (+0.22%)
     
  • Gold

    1,869.30
    +1.30 (+0.07%)
     
  • Silver

    23.34
    -0.02 (-0.06%)
     
  • EUR/USD

    1.1675
    -0.0003 (-0.0234%)
     
  • 10-Yr Bond

    0.8350
    0.0000 (0.00%)
     
  • Vix

    39.46
    -0.82 (-2.04%)
     
  • GBP/USD

    1.2932
    +0.0009 (+0.0672%)
     
  • USD/JPY

    104.3610
    -0.2490 (-0.2380%)
     
  • BTC-USD

    13,203.70
    -170.48 (-1.27%)
     
  • CMC Crypto 200

    258.48
    +15.80 (+6.51%)
     
  • FTSE 100

    5,573.04
    -8.71 (-0.16%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

Zacks Equity Research
·2 mins read

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $44.67, moving +0.84% from the previous trading session. This move lagged the S&P 500's daily gain of 4.94%. Elsewhere, the Dow gained 4.89%, while the tech-heavy Nasdaq added 4.95%.

Coming into today, shares of the company had lost 21.76% in the past month. In that same time, the Medical sector lost 10.63%, while the S&P 500 lost 17.66%.

Investors will be hoping for strength from CRSP as it approaches its next earnings release. The company is expected to report EPS of -$1.09, down 17.2% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $6.35 million, up 1824.24% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.54 per share and revenue of $29.11 million. These totals would mark changes of -488.03% and -89.95%, respectively, from last year.

Any recent changes to analyst estimates for CRSP should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.4% higher. CRSP is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 100, which puts it in the top 40% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.